Martin Shkreli: Valeant Worth $28.37/Share

It's no secret Valeant Pharmaceuticals Intl Inc VRX shares had an awful Tuesday. In the afternoon, ex-pharma exec-turned hedge fund manager-turned FBI fraud target Martin Shkreli analyzed the company on his YouTube channel.

According to several tweets recapping the episode, Shkreli valued Valeant at about $28.37 per share. He also added that he doesn't think Valeant is worth shorting, according to Twitter.

Additionally, files publicly shared by Shkreli suggest he's forecasting a gross margin decline for Valeant from 77 percent in 2016 to 70 percent by 2025.

Valeant shares closed Tuesday at $33.54. They were above $200 a year ago.

The live stream is still rolling, below.